Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

4results about How to "High labeling yield" patented technology

Glutamic acid urea compound and preparation method and application thereof, nuclide targeting probe and preparation method and application thereof, and pharmaceutical composition

The invention belongs to the technical field of biological medicines, and particularly relates to a glutamic acid urea compound and a preparation method and application thereof, a nuclide targeting probe and a preparation method and application thereof, and a pharmaceutical composition. The glutamic acid urea compound and the nuclide targeting probe provided by the invention have excellent in-vivo biological performance, have high specific uptake, high target-to-non-target ratio and low non-specific background activity in PSMA protein high-expression focuses, and have remarkably enhanced tumor uptake and retention time; the compound is suitable for nuclide treatment and imaging of tumors, can reduce unnecessary radioactive damage to normal tissues and organs, can overcome the defects that small-molecule PSMA target organs are relatively low in uptake and too short in retention time, can improve targeted PSMA nuclide treatment and imaging effects, and has the potential of being clinically popularized and applied.
Owner:XIAMEN UNIV

Cyclic TMTP1 polypeptide ligand radioactive probe as well as preparation method and application thereof

The structural formula of the cyclic TMTP1 polypeptide ligand is Cyclo [K (NOTA) NVvRQ], the cyclic TMTP1 polypeptide ligand is structurally modified, after radiolabeling, the biological activity of the cyclic TMTP1 polypeptide ligand is not affected, the labeling method is simple, the labeling yield is high, and the cyclic TMTP1 polypeptide ligand has the biological characteristic of specifically targeting a high metastatic tumor and can be used for early diagnosis of the high metastatic tumor.
Owner:THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIV

STING-targeted precursor compound, nuclide marker, preparation method and application of nuclide marker, pharmaceutical composition and application of pharmaceutical composition

The invention relates to the technical field of radiopharmaceuticals and medical imaging, in particular to an STING-targeted precursor compound, a nuclide marker, a preparation method and application of the STING-targeted precursor compound, a nuclide marker, a pharmaceutical composition and application of the pharmaceutical composition. The STING targeting precursor compound, the pharmaceutically acceptable form of the STING targeting precursor compound, the nuclide marker of the STING targeting precursor compound and the pharmaceutically acceptable form of the STING targeting precursor compound have excellent in-vivo biological performance, can have high specific uptake in tumors or inflammations with high expression of interferon stimulating factors STING, has a high target-to-non-target ratio, and can be used for preparing the target-to-non-target tumor marker of the STING targeting precursor compound and the nuclide marker of the STING targeting precursor compound and the pharmaceutically acceptable form of the STING targeting precursor compound and the nuclide marker of the STING targeting precursor compound. And the non-specific background is low, and unnecessary radioactive injury can be reduced by lower non-target visceral organ uptake, so that the medication safety is high.
Owner:XIAMEN UNIV